Led · Seed · Jul 2026

Aurenar's core product, V-Link, is a simple, wireless, single-use transauricular vagus nerve stimulation device designed to modulate the body's inflammatory response in critically ill patients. The platform was developed from research at Washington University School of Medicine and has received FDA breakthrough device designation. Clinical work cited by the company includes a randomized subarachnoid hemorrhage (SAH) trial reporting a greater than 40% reduction in moderate-to-severe vasospasm, lowered pro-inflammatory cytokines, improved functional outcomes, and a companion analysis showing a 20% drop in 30-day modifiable hospitalization costs; a separate large-vessel occlusion (LVO) ischemic stroke trial reportedly showed consistent anti-inflammatory effects and a clean safety profile. V-Link's wireless design is intended to simplify use by neuro-intensive care physicians and ICU nursing staff to support faster onboarding and adoption. Headquartered in St. Louis, Aurenar plans to use its newly raised seed capital to complete device development, V&V testing, and regulatory submissions ahead of pivotal trials.

Participated · Series A · Apr 2026

SimpliFed offers virtual breastfeeding and baby feeding support and broader maternal health care from pregnancy through the postpartum period via a secure, HIPAA-compliant telehealth platform. The company connects parents with a network of baby feeding experts and maternal health specialists and operates a proprietary Maternal Health operating system designed for collaboration with healthcare partners. Its platform uses interoperable infrastructure and API-driven technology to integrate with health plans, providers, partners and health systems for secure data exchange and streamlined workflows. SimpliFed intends to expand those partnerships and scale use of its Maternal Health OS following its Series A. The company is led by founder and CEO Andrea Ippolito and is based in New York City. The recent Series A raised over $10M to support platform growth and partner activation.

Participated · Seed · Dec 2025

Auxira Health operates a virtual cardiology platform that pairs advanced practice providers, medical assistants and registered nurses with cardiology practices as fully integrated remote “pods.” These virtual teams handle clinical and administrative tasks, allowing on-site cardiologists to see more patients and reduce workload. The company partners with cardiology groups and health systems nationwide, positioning its service as a scalable way to address specialist shortages and administrative burden. Led by CEO Inna Plumb, Auxira Health is building out technology and operational infrastructure to support seamless integration with partner clinics. The firm plans to hire additional clinicians and support staff to meet rising demand. By mid-2026, management expects the platform to support more than 100 cardiologists. The recent seed funding provides the financial runway to accelerate these growth initiatives and deepen product capabilities.

Participated · Equity · Dec 2025

Empathy Health Technologies is the company behind Sober Sidekick, a free mobile application that connects individuals battling substance-use disorders with a 24/7 peer community, daily motivation, professional help and on-demand AA meetings. The app encourages users to both give and receive supportive messages and leverages an “empathy algorithm” that analyzes behavioral and language patterns to predict relapse risk, automatically triggering outreach when danger signs surface. Sober Sidekick has been downloaded nearly 1.1 million times, serves more than 145,000 monthly active users and has facilitated over 2 million peer interactions; an independent analysis found that five interactions on the platform correlate with a 68 % lower likelihood of relapse. While anyone can download the app for free, the company also signs value-based contracts with commercial and public payers. Revenue details were not disclosed, but Empathy Health intends to build a continuous-care infrastructure that shifts reimbursement from crisis response to relapse prevention. With its newest capital, the firm plans to deepen payer partnerships, enhance its predictive technology, and expand member-support operations, including data-science capacity and care-navigation infrastructure. Founded by CEO Chris Thompson, who drew on his own recovery experience, the company ultimately aims to redefine success in substance-use care by measuring sustained relapse prevention rather than episodic treatment.

Led · Series A · Sep 2025

Neura Health operates a virtual neurology clinic aimed at improving access and quality of care for patients suffering from chronic neurological conditions such as migraine, sleep disorders, seizures, TBI, stroke, tremors, long COVID, and memory disorders. The platform combines tele-neurology visits with integrated symptom tracking, personalized educational content, and dedicated care coaching. Since launch, the company has treated more than 43,000 patients across the United States and partners with health systems like Sentara Health to extend neurology capacity. It is in-network with over 40 health plans, including Aetna, Blue Shield of California, Cigna, Anthem Blue Cross, TriWest, and Medicare, which broadens patient affordability and reach. Co-founded by Elizabeth Burstein and Sameer Madan, Neura Health plans to use new capital to scale operations and advance product development. The company has now raised a cumulative $22 million in venture funding, reflecting growing investor confidence in its tele-neurology approach. No revenue figures were disclosed in the article, but the patient volume and payer relationships indicate early commercial traction.